Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion.
Two patients with ischaemic central retinal vein occlusion were treated with intracameral bevacizumab in order to affect the outcome of their disease. In addition, both patients underwent episodes of cycloablative and pan-retinal laser treatment. The patients were followed for more than 6 months and achieved some stability with a combination of these modalities.
Qureshi
Kashif
K
Bolton Hospitals NHS Trust, Bolton Eye Unit, Bolton NHS Trust, Minerva Road, Farnworth, Bolton, BL4 0JR, UK. Kashif.Qureshi@btinternet.com
Kashani
Shahram
S
Kelly
Simon P
SP
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000867:Anterior Chamber; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
Ophthalmologe. 2007 Nov;104(11):952-7
17965862
Indian J Ophthalmol. 2007 Nov-Dec;55(6):460-2
17951906
Br J Ophthalmol. 2006 Nov;90(11):1344-9
16854824
Eur J Ophthalmol. 2008 Mar-Apr;18(2):255-62
18320519
J Glaucoma. 2007 Aug;16(5):437-9
17700285
Am J Ophthalmol. 2006 Jul;142(1):158-60
16815268